Xinlan N. Liu
Yinchuan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: a prospective, single-arm, phase 2 study.
Journal: BMC medicine
Published: October 15, 2025
Utidelone Plus Bevacizumab for ERBB2-Negative Metastatic Breast Cancer and Active Brain Metastases: The U-BOMB Phase 2 Nonrandomized Clinical Trial.
Journal: JAMA oncology
Published: June 26, 2025
HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial).
Journal: Signal transduction and targeted therapy
Published: May 27, 2025
D-Mannose Upregulates Testin via the NF-κB Pathway to Inhibit Breast Cancer Proliferation.
Journal: Journal of biochemical and molecular toxicology
Published: February 23, 2025
Application of Neoadjuvant Docetaxel plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 24, 2025
A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer.
Journal: Future oncology (London, England)
Published: December 04, 2024
Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer: the phase 2 NeoSAC trial.
Journal: Signal transduction and targeted therapy
Published: September 20, 2024
Effect of Adding Electroacupuncture to Standard Triple Antiemetic Therapy on Chemotherapy-Induced Nausea and Vomiting: A Randomized Controlled Clinical Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 06, 2024
Nomogram for predicting the risk and prognosis of lung metastasis of four subtypes of breast cancer: A population-based study from SEER.
Journal: Cancer pathogenesis and therapy
Published: March 30, 2024
Lerociclib plus fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial.
Journal: Nature communications
Published: December 28, 2023
Validation of CTS5 Model in Large-scale Breast Cancer Population and Combination of CTS5 and Ki-67 Status to Develop a Novel Nomogram for Prognosis Prediction.
Journal: American journal of clinical oncology
Published: December 22, 2023
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 22, 2023
Last Updated: 09/26/2026